Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Willis Tower Watson in its divestment of Max Matthiessen
Mandate

Vinge advises Willis Tower Watson in its divestment of Max Matthiessen

May 25, 2020 Banking and Finance EU, Competition and Regulatory M&A Insurance Law Corporate Tax

Vinge advises Willis Tower Watson, global risk adviser, insurance and reinsurance broker, in its divestment of Max Matthiessen to Nordic Capital.

Max Matthiessen was founded 1889 and as active in insurance brokerage and financial advisory services for companies and individuals. The company has 440 employees at approximately 30 locations throughout Sweden with headquarter in Stockholm. In 2019, Max Matthiessen had a customer base of around 13,000 clients with revenues exceeding SEK 1.5 billion. Willis Tower Watson acquired Max Matthiessen from Altor 2014.

The acquisition is conditional upon customary regulatory approvals and conditions to closing.

Vinge’s team consisted of, amongst others, Peter Sundgren, Joacim Rydergård, Stina Bengtsson and Olivia Belding (M&A), Fabian Ekeblad and Paulina Malmberg (Regulatory Insurance), Albert Wållgren (Banking & Finance), Maria Schultzberg (Tax), Xandra Ståhlberg (Competition law) and Nathalie Hughes (VDR-assistant).

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026